Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant
A. Weiss, F. Touret, C. Baronti, M. Gilles, B. Hoen, A. Nougairede, X. de Lamballerie, M. O. A. Sommer
This study shows niclosamide is effective against SARS-CoV-2 and its variants in a human airway model, supporting its potential as a COVID-19 therapy.
bioRxiv · Apr 26, 2021Microbiology